{"id":64758,"date":"2026-05-08T20:10:03","date_gmt":"2026-05-08T12:10:03","guid":{"rendered":"https:\/\/flcube.com\/?p=64758"},"modified":"2026-05-08T20:11:25","modified_gmt":"2026-05-08T12:11:25","slug":"chinas-national-drug-alliance-procurement-office-suspends-harbin-liqiangs-loxoprofen-gel-patch-production-and-imposes-18-month-vbp-ban","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64758","title":{"rendered":"China&#8217;s National Drug Alliance Procurement Office Suspends Harbin Liqiang&#8217;s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban"},"content":{"rendered":"\n<p>The <strong>National Drug Alliance Procurement Office<\/strong>, administrator of China&#8217;s <strong>volume-based procurement (VBP) program<\/strong>, announced the <strong>manufacturing suspension<\/strong> of <strong>loxoprofen gel patch<\/strong> by <strong>Harbin Liqiang Pharmaceutical Co., Ltd.<\/strong>, following the company&#8217;s failure to fulfill supply obligations as a winning bidder in the <strong>11th round of VBP<\/strong>. The regulatory body has <strong>revoked Liqiang Pharma&#8217;s winning bid status<\/strong> and imposed an <strong>18-month ban<\/strong> on VBP participation from <strong>April 30, 2026, to October 29, 2027<\/strong>, signaling strict enforcement of supply chain reliability requirements in China&#8217;s pharmaceutical procurement system. <\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-action-summary\">Regulatory Action Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product Affected<\/strong><\/td><td>Loxoprofen gel patch (NSAID topical formulation)<\/td><\/tr><tr><td><strong>VBP Round<\/strong><\/td><td>11th round of China&#8217;s volume-based procurement<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Harbin Liqiang Pharmaceutical Co., Ltd.<\/td><\/tr><tr><td><strong>Action Taken<\/strong><\/td><td>Manufacturing suspension and winning bid status revocation<\/td><\/tr><tr><td><strong>Ban Period<\/strong><\/td><td>April 30, 2026 \u2013 October 29, 2027 (18 months)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>National Drug Alliance Procurement Office<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-vbp-program-enforcement-framework\">VBP Program Enforcement Framework<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-supply-obligation-requirements\">Supply Obligation Requirements<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Contract Compliance<\/strong>: Winning bidders must maintain consistent supply throughout contract period<\/li>\n\n\n\n<li><strong>Quality Standards<\/strong>: Products must meet pharmacopeial specifications and GMP requirements<\/li>\n\n\n\n<li><strong>Delivery Timelines<\/strong>: Strict adherence to agreed-upon delivery schedules across participating provinces<\/li>\n\n\n\n<li><strong>Capacity Assurance<\/strong>: Manufacturers must demonstrate adequate production capacity before bid submission<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-penalty-structure-for-non-compliance\">Penalty Structure for Non-Compliance<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Immediate Suspension<\/strong>: Production halt for affected products upon violation confirmation<\/li>\n\n\n\n<li><strong>Bid Status Revocation<\/strong>: Loss of preferential market access and guaranteed volume commitments<\/li>\n\n\n\n<li><strong>Participation Ban<\/strong>: Temporary exclusion from future VBP rounds ranging from 6\u201324 months<\/li>\n\n\n\n<li><strong>Reputation Impact<\/strong>: Public disclosure affecting company credibility with healthcare institutions<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-assessment\">Market Impact Assessment<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-immediate-supply-chain-disruption\">Immediate Supply Chain Disruption<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Access<\/strong>: Potential temporary shortage of loxoprofen gel patches in VBP-covered regions<\/li>\n\n\n\n<li><strong>Alternative Sourcing<\/strong>: Healthcare institutions required to identify substitute NSAID topical formulations<\/li>\n\n\n\n<li><strong>Price Pressure<\/strong>: Non-VBP alternatives may command premium pricing during supply gap<\/li>\n\n\n\n<li><strong>Provincial Coordination<\/strong>: Individual provinces managing emergency procurement procedures<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-landscape-shift\">Competitive Landscape Shift<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Opportunity<\/strong>: Competing manufacturers of topical NSAIDs positioned to capture displaced demand<\/li>\n\n\n\n<li><strong>VBP Successor<\/strong>: Alternative supplier likely to be designated through emergency procurement mechanisms<\/li>\n\n\n\n<li><strong>Pricing Dynamics<\/strong>: Potential temporary price increases for non-banned loxoprofen formulations<\/li>\n\n\n\n<li><strong>Brand Substitution<\/strong>: Increased adoption of alternative NSAID brands including diclofenac and ketoprofen patches<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-wide-implications\">Industry-Wide Implications<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-vbp-program-credibility\">VBP Program Credibility<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Enforcement Precedent<\/strong>: Demonstrates zero-tolerance approach to supply chain failures<\/li>\n\n\n\n<li><strong>Deterrent Effect<\/strong>: Sends strong signal to other manufacturers about compliance expectations<\/li>\n\n\n\n<li><strong>System Reliability<\/strong>: Reinforces VBP program&#8217;s commitment to uninterrupted patient access<\/li>\n\n\n\n<li><strong>Quality Focus<\/strong>: Emphasizes that lowest-price bidding must be accompanied by supply capability<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-manufacturer-risk-management\">Manufacturer Risk Management<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capacity Planning<\/strong>: Companies must conduct thorough production capacity assessments before VBP participation<\/li>\n\n\n\n<li><strong>Supply Chain Resilience<\/strong>: Need for redundant manufacturing capabilities and raw material security<\/li>\n\n\n\n<li><strong>Financial Preparedness<\/strong>: Adequate capital reserves to support sustained low-margin VBP operations<\/li>\n\n\n\n<li><strong>Regulatory Compliance<\/strong>: Enhanced focus on GMP adherence and quality management systems<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-business-consequences-for-liqiang-pharma\">Strategic Business Consequences for Liqiang Pharma<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-financial-impact\">Financial Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Loss<\/strong>: Immediate elimination of guaranteed VBP volumes representing significant revenue stream<\/li>\n\n\n\n<li><strong>Market Share Erosion<\/strong>: Extended absence from China&#8217;s largest pharmaceutical procurement channel<\/li>\n\n\n\n<li><strong>Reputation Damage<\/strong>: Long-term impact on relationships with hospitals and provincial health authorities<\/li>\n\n\n\n<li><strong>Operational Costs<\/strong>: Fixed costs continuing despite loss of primary revenue source<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-recovery-timeline\">Recovery Timeline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ban Duration<\/strong>: 18-month exclusion represents substantial competitive disadvantage<\/li>\n\n\n\n<li><strong>Re-entry Requirements<\/strong>: Must demonstrate improved supply chain capabilities for future VBP participation<\/li>\n\n\n\n<li><strong>Market Rebuilding<\/strong>: Significant investment required to regain institutional trust and market position<\/li>\n\n\n\n<li><strong>Strategic Repositioning<\/strong>: Potential need to focus on non-VBP segments or international markets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-policy-context-and-future-outlook\">Policy Context and Future Outlook<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-vbp-program-evolution\">VBP Program Evolution<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Maturity Phase<\/strong>: China&#8217;s VBP program transitioning from expansion to enforcement and optimization<\/li>\n\n\n\n<li><strong>Quality Emphasis<\/strong>: Increasing focus on supply reliability alongside price competition<\/li>\n\n\n\n<li><strong>Manufacturer Screening<\/strong>: Enhanced pre-qualification requirements for future bidding rounds<\/li>\n\n\n\n<li><strong>Monitoring Systems<\/strong>: Implementation of real-time supply chain monitoring and early warning systems<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-broader-healthcare-system-impact\">Broader Healthcare System Impact<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Protection<\/strong>: Ensuring continuity of essential medicine access remains paramount<\/li>\n\n\n\n<li><strong>Cost Control Balance<\/strong>: Maintaining affordability while preventing supply disruptions<\/li>\n\n\n\n<li><strong>Domestic Industry Development<\/strong>: Encouraging sustainable business models among Chinese pharmaceutical companies<\/li>\n\n\n\n<li><strong>International Precedent<\/strong>: China&#8217;s VBP enforcement approach potentially influencing global procurement policies<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the impact of regulatory actions, market dynamics, and policy developments. Actual outcomes may vary due to implementation details, competitive responses, and evolving regulatory frameworks.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The National Drug Alliance Procurement Office, administrator of China&#8217;s volume-based procurement (VBP) program, announced the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[4],"tags":[4728,82],"class_list":["post-64758","post","type-post","status-publish","format-standard","hentry","category-policy-regulatory","tag-liqiang-pharmaceutical","tag-vbp-voluem-based-procurement"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China&#039;s National Drug Alliance Procurement Office Suspends Harbin Liqiang&#039;s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The National Drug Alliance Procurement Office, administrator of China&#039;s volume-based procurement (VBP) program, announced the manufacturing suspension of loxoprofen gel patch by Harbin Liqiang Pharmaceutical Co., Ltd., following the company&#039;s failure to fulfill supply obligations as a winning bidder in the 11th round of VBP. The regulatory body has revoked Liqiang Pharma&#039;s winning bid status and imposed an 18-month ban on VBP participation from April 30, 2026, to October 29, 2027, signaling strict enforcement of supply chain reliability requirements in China&#039;s pharmaceutical procurement system.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64758\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China&#039;s National Drug Alliance Procurement Office Suspends Harbin Liqiang&#039;s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban\" \/>\n<meta property=\"og:description\" content=\"The National Drug Alliance Procurement Office, administrator of China&#039;s volume-based procurement (VBP) program, announced the manufacturing suspension of loxoprofen gel patch by Harbin Liqiang Pharmaceutical Co., Ltd., following the company&#039;s failure to fulfill supply obligations as a winning bidder in the 11th round of VBP. The regulatory body has revoked Liqiang Pharma&#039;s winning bid status and imposed an 18-month ban on VBP participation from April 30, 2026, to October 29, 2027, signaling strict enforcement of supply chain reliability requirements in China&#039;s pharmaceutical procurement system.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64758\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-08T12:10:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T12:11:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64758#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64758\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China&#8217;s National Drug Alliance Procurement Office Suspends Harbin Liqiang&#8217;s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban\",\"datePublished\":\"2026-05-08T12:10:03+00:00\",\"dateModified\":\"2026-05-08T12:11:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64758\"},\"wordCount\":681,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Liqiang Pharmaceutical\",\"VBP (voluem-based procurement)\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64758#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64758\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64758\",\"name\":\"China's National Drug Alliance Procurement Office Suspends Harbin Liqiang's Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-08T12:10:03+00:00\",\"dateModified\":\"2026-05-08T12:11:25+00:00\",\"description\":\"The National Drug Alliance Procurement Office, administrator of China's volume-based procurement (VBP) program, announced the manufacturing suspension of loxoprofen gel patch by Harbin Liqiang Pharmaceutical Co., Ltd., following the company's failure to fulfill supply obligations as a winning bidder in the 11th round of VBP. The regulatory body has revoked Liqiang Pharma's winning bid status and imposed an 18-month ban on VBP participation from April 30, 2026, to October 29, 2027, signaling strict enforcement of supply chain reliability requirements in China's pharmaceutical procurement system.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64758#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64758\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64758#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China&#8217;s National Drug Alliance Procurement Office Suspends Harbin Liqiang&#8217;s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China's National Drug Alliance Procurement Office Suspends Harbin Liqiang's Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban - Insight, China&#039;s Pharmaceutical Industry","description":"The National Drug Alliance Procurement Office, administrator of China's volume-based procurement (VBP) program, announced the manufacturing suspension of loxoprofen gel patch by Harbin Liqiang Pharmaceutical Co., Ltd., following the company's failure to fulfill supply obligations as a winning bidder in the 11th round of VBP. The regulatory body has revoked Liqiang Pharma's winning bid status and imposed an 18-month ban on VBP participation from April 30, 2026, to October 29, 2027, signaling strict enforcement of supply chain reliability requirements in China's pharmaceutical procurement system.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64758","og_locale":"en_US","og_type":"article","og_title":"China's National Drug Alliance Procurement Office Suspends Harbin Liqiang's Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban","og_description":"The National Drug Alliance Procurement Office, administrator of China's volume-based procurement (VBP) program, announced the manufacturing suspension of loxoprofen gel patch by Harbin Liqiang Pharmaceutical Co., Ltd., following the company's failure to fulfill supply obligations as a winning bidder in the 11th round of VBP. The regulatory body has revoked Liqiang Pharma's winning bid status and imposed an 18-month ban on VBP participation from April 30, 2026, to October 29, 2027, signaling strict enforcement of supply chain reliability requirements in China's pharmaceutical procurement system.","og_url":"https:\/\/flcube.com\/?p=64758","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-08T12:10:03+00:00","article_modified_time":"2026-05-08T12:11:25+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64758#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64758"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China&#8217;s National Drug Alliance Procurement Office Suspends Harbin Liqiang&#8217;s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban","datePublished":"2026-05-08T12:10:03+00:00","dateModified":"2026-05-08T12:11:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64758"},"wordCount":681,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Liqiang Pharmaceutical","VBP (voluem-based procurement)"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64758#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64758","url":"https:\/\/flcube.com\/?p=64758","name":"China's National Drug Alliance Procurement Office Suspends Harbin Liqiang's Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-08T12:10:03+00:00","dateModified":"2026-05-08T12:11:25+00:00","description":"The National Drug Alliance Procurement Office, administrator of China's volume-based procurement (VBP) program, announced the manufacturing suspension of loxoprofen gel patch by Harbin Liqiang Pharmaceutical Co., Ltd., following the company's failure to fulfill supply obligations as a winning bidder in the 11th round of VBP. The regulatory body has revoked Liqiang Pharma's winning bid status and imposed an 18-month ban on VBP participation from April 30, 2026, to October 29, 2027, signaling strict enforcement of supply chain reliability requirements in China's pharmaceutical procurement system.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64758#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64758"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64758#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China&#8217;s National Drug Alliance Procurement Office Suspends Harbin Liqiang&#8217;s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64758","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64758"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64758\/revisions"}],"predecessor-version":[{"id":64761,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64758\/revisions\/64761"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64758"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64758"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64758"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}